Back to Search
Start Over
Experience of targeted therapy for ALK positive non-small cell lung cancer – a clinical case
- Source :
- Медицинский совет, Vol 0, Iss 20, Pp 181-186 (2020)
- Publication Year :
- 2020
- Publisher :
- Remedium, Ltd., 2020.
-
Abstract
- Lung cancer holds a leading position in the cancer mortality pattern worldwide. The emergence of knowledge about driver mutations heralded a new era in the targeted therapy for lung carcinomas. ALK translocation is identified in 5–7% of non-small cell lung cancer cases. ALK-positive lung adenocarcinomas are associated with specific clinical features, including no or light smoking history and younger age. Alectinib is a novel ALK inhibitor that has been granted a breakthrough therapy status by the FDA to accelerate approval as a second-line therapy after progression during crizotinib therapy.Here, the case of a patient with metastatic ALK-positive lung adenocarcinoma treated with alectinib has been discussed. Molecular genetic testing for driver mutations makes it possible to personalize approaches to anticancer drug therapy. At the same time, the custom-compounded targeted therapy is more often accompanied by significant objective responses and moderate symptoms of toxicity, which is relevant for patients in critical condition. The experience in using alectinib demonstrates the possibility of its long-term administration with high efficiency and a controlled safety profile.
- Subjects :
- 0301 basic medicine
Oncology
medicine.medical_specialty
medicine.medical_treatment
Targeted therapy
03 medical and health sciences
0302 clinical medicine
alk inhibitors
Internal medicine
medicine
alectinib
Lung cancer
non-small cell lung cancer
adenocarcinoma
business.industry
ALK-Positive
General Medicine
medicine.disease
030104 developmental biology
030220 oncology & carcinogenesis
alk translocation
Medicine
Non small cell
Clinical case
business
progression-free survival
Subjects
Details
- ISSN :
- 26585790 and 2079701X
- Database :
- OpenAIRE
- Journal :
- Meditsinskiy sovet = Medical Council
- Accession number :
- edsair.doi.dedup.....9f5972a927ce2702d0e42e5dad906da6